Brief: Astellas Pharma Inc - Sales In U.S. Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Treatment Of Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration In Q1 Of Fy2025 Was ¥15.9 Billion/ $110 Million
10/07/2025 24:32
July 10 (Reuters) - Astellas Pharma Inc 4503.T: ASTELLAS PHARMA INC: SALES IN U.S. OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR TREATMENT OF GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION IN Q1 OF FY2025 WAS ¥15.9 BILLION/ $110 MILLION Source text: ID:nTSsi7cc36 Further company coverage: 4503.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)